Pricing Log in Create free account

Coherus Oncology, Inc. (CHRS) vs Molecular Partners AG Sponsored ADR (MOLN)

Coherus Oncology, Inc. and Molecular Partners AG Sponsored ADR are both Biotechnology companies. Coherus Oncology, Inc. and Molecular Partners AG Sponsored ADR are of similar size ($119.2M and $119.0M). Coherus Oncology, Inc. grew revenue faster over the last twelve months: 61.0% against −28.0%. Molecular Partners AG Sponsored ADR has the higher net margin (0.00% vs −259.4%) and the higher return on invested capital (0.00% vs 0.00%). Across the 18 metrics below, Coherus Oncology, Inc. leads on 9 and Molecular Partners AG Sponsored ADR on 9.

Valuation

Metric CHRS MOLN Biotechnology median
P/E n/m n/m 10.60
P/S 2.34 21.86 9.40
P/B 1.96 1.98 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 4.44 9.32 9.02
Earnings yield (133.77%) (52.05%) (32.88%)
Free cash flow yield (156.84%) (45.19%) (23.13%)

Profitability

Metric CHRS MOLN Biotechnology median
Gross margin 68.94% 0.00% 68.51%
Operating margin (311.56%) 0.00% 0.00%
Net margin (259.41%) 0.00% 0.00%
Free cash flow margin (365.22%) 0.00% 0.00%
Return on equity (146.27%) (71.08%) (51.96%)
Return on assets (41.90%) (58.83%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CHRS MOLN Biotechnology median
Revenue growth (TTM) 61.00% (27.99%) 6.76%
EPS growth (last fiscal year) 472.00% (9.94%) 29.88%
Revenue growth, 5-year CAGR (38.41%) (23.12%) 9.75%
Net income growth, 5-year CAGR 4.91% 0.00% 0.00%

Health

Metric CHRS MOLN Biotechnology median
Debt to equity 0.61 0.00 0.00
Current ratio 1.77 6.46 4.97
Net debt to EBITDA 0.76 1.66 1.01

Dividend

Metric CHRS MOLN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CHRS MOLN Biotechnology median
Market cap 118.97m 119.24m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack